| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
An analysis of cancer patients with asymptomatic infection of SARS-CoV-2 in a cancer center in Wuhan, China
|
Yin, P.
|
|
|
31 |
10 |
p. 1420-1422
|
article
|
| 2 |
Androgen deprivation and SARS-CoV-2 in men with prostate cancer
|
Koskinen, M.
|
|
|
31 |
10 |
p. 1417-1418
|
article
|
| 3 |
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
|
Park, S.
|
|
|
31 |
10 |
p. 1397-1404
|
article
|
| 4 |
Clinical development of therapies targeting TGFβ: current knowledge and future perspectives
|
Ciardiello, D.
|
|
|
31 |
10 |
p. 1336-1349
|
article
|
| 5 |
Conceptual and clinical interpretation of 2007 WCRF/AICR score in relation to cancer-related health outcomes
|
Jayaraj, R.
|
|
|
31 |
10 |
p. 1413-1414
|
article
|
| 6 |
Corrigendum to “Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials”
|
Franzoi, M.A.
|
|
|
31 |
10 |
p. 1423
|
article
|
| 7 |
COVID-19 in patients with lung cancer
|
Luo, J.
|
|
|
31 |
10 |
p. 1386-1396
|
article
|
| 8 |
Does androgen deprivation therapy protect against severe complications from COVID-19?
|
Patel, V.G.
|
|
|
31 |
10 |
p. 1419-1420
|
article
|
| 9 |
Editorial Board
|
|
|
|
31 |
10 |
p. iv
|
article
|
| 10 |
Elapsed time for an unresolved adverse event: systemic anticancer therapy-induced neurotoxicity calls for action
|
Antonuzzo, A.
|
|
|
31 |
10 |
p. 1289-1290
|
article
|
| 11 |
First case of persistent pancytopenia associated with SARS-CoV-2 bone marrow infiltration in an immunocompromised patient
|
Issa, N.
|
|
|
31 |
10 |
p. 1418-1419
|
article
|
| 12 |
Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer
|
Serna, G.
|
|
|
31 |
10 |
p. 1366-1375
|
article
|
| 13 |
Fusobacterium nucleatum, rectal cancer and radiotherapy
|
Mann, E.H.
|
|
|
31 |
10 |
p. 1277-1278
|
article
|
| 14 |
Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study
|
Luen, S.J.
|
|
|
31 |
10 |
p. 1359-1365
|
article
|
| 15 |
Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial ☆
|
Glynne-Jones, R.
|
|
|
31 |
10 |
p. 1376-1385
|
article
|
| 16 |
Inhibiting fibroblast growth factor receptors in cancer – the next generation
|
Schuler, M.
|
|
|
31 |
10 |
p. 1285-1286
|
article
|
| 17 |
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
|
Argilés, G.
|
|
|
31 |
10 |
p. 1291-1305
|
article
|
| 18 |
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
|
Curigliano, G.
|
|
|
31 |
10 |
p. 1320-1335
|
article
|
| 19 |
New guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing
|
Tarazona, N.
|
|
|
31 |
10 |
p. 1287-1288
|
article
|
| 20 |
On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2
|
Caffo, O.
|
|
|
31 |
10 |
p. 1415-1416
|
article
|
| 21 |
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors
|
Bahleda, R.
|
|
|
31 |
10 |
p. 1405-1412
|
article
|
| 22 |
Reevaluating the role of antibody–drug conjugates in the treatment of patients with brain metastases
|
Lin, N.U.
|
|
|
31 |
10 |
p. 1279-1281
|
article
|
| 23 |
Response to the letter to the editor ‘Conceptual and clinical interpretation of 2007 WCRF/AICR Score in relation to cancer-related health outcomes’, by R. Jayaraj, et al.
|
Solans, M.
|
|
|
31 |
10 |
p. 1414-1415
|
article
|
| 24 |
Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up
|
Jordan, B.
|
|
|
31 |
10 |
p. 1306-1319
|
article
|
| 25 |
Table of Contents
|
|
|
|
31 |
10 |
p. i-ii
|
article
|
| 26 |
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆
|
Montemurro, F.
|
|
|
31 |
10 |
p. 1350-1358
|
article
|
| 27 |
Treatment compliance in early-stage anal cancer
|
Pretta, A.
|
|
|
31 |
10 |
p. 1282-1284
|
article
|
Journal description